Shiv Kumar Agarwal
Concepts (293)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 21 | 2026 | 224 | 7.260 |
Why?
| | Percutaneous Coronary Intervention | 14 | 2022 | 329 | 2.940 |
Why?
| | Fractional Flow Reserve, Myocardial | 9 | 2022 | 127 | 2.270 |
Why?
| | Coronary Artery Disease | 9 | 2022 | 324 | 1.940 |
Why?
| | Diabetes Mellitus | 6 | 2024 | 321 | 1.580 |
Why?
| | Coronary Stenosis | 3 | 2021 | 99 | 1.240 |
Why?
| | Blood Glucose | 12 | 2024 | 490 | 1.220 |
Why?
| | Blood Glucose Self-Monitoring | 8 | 2024 | 47 | 1.200 |
Why?
| | Hospitalization | 9 | 2026 | 749 | 1.200 |
Why?
| | Community Health Workers | 2 | 2026 | 62 | 1.110 |
Why?
| | Humans | 70 | 2026 | 53230 | 0.940 |
Why?
| | Coronary Occlusion | 3 | 2021 | 80 | 0.900 |
Why?
| | Coronary Angiography | 11 | 2022 | 369 | 0.900 |
Why?
| | Treatment Outcome | 20 | 2022 | 5595 | 0.770 |
Why?
| | Ecosystem | 1 | 2023 | 99 | 0.730 |
Why?
| | Technology | 4 | 2022 | 21 | 0.730 |
Why?
| | Racism | 1 | 2023 | 61 | 0.720 |
Why?
| | Young Adult | 15 | 2026 | 4511 | 0.720 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2026 | 630 | 0.670 |
Why?
| | Aneurysm, False | 1 | 2020 | 44 | 0.640 |
Why?
| | Transition to Adult Care | 2 | 2016 | 24 | 0.620 |
Why?
| | Male | 41 | 2026 | 27435 | 0.600 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2024 | 591 | 0.600 |
Why?
| | Skin | 2 | 2019 | 419 | 0.580 |
Why?
| | Hemodynamics | 2 | 2017 | 236 | 0.580 |
Why?
| | Myocardial Ischemia | 2 | 2016 | 129 | 0.550 |
Why?
| | Coronary Vessels | 5 | 2021 | 170 | 0.550 |
Why?
| | Female | 34 | 2026 | 28782 | 0.520 |
Why?
| | Glucocorticoids | 1 | 2019 | 236 | 0.510 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 233 | 0.500 |
Why?
| | Renal Dialysis | 6 | 2018 | 196 | 0.500 |
Why?
| | Adolescent | 15 | 2026 | 6907 | 0.490 |
Why?
| | Vibrio cholerae | 1 | 2015 | 1 | 0.480 |
Why?
| | Phospholipases A1 | 1 | 2015 | 1 | 0.480 |
Why?
| | Cholera | 1 | 2015 | 2 | 0.480 |
Why?
| | Angioplasty, Balloon | 2 | 2019 | 69 | 0.470 |
Why?
| | Cardiac Catheterization | 4 | 2020 | 229 | 0.470 |
Why?
| | Diabetes Complications | 3 | 2021 | 124 | 0.470 |
Why?
| | Phosphatidylinositol Phosphates | 1 | 2015 | 17 | 0.470 |
Why?
| | Endosomes | 1 | 2015 | 35 | 0.470 |
Why?
| | Bacterial Toxins | 1 | 2015 | 52 | 0.460 |
Why?
| | Postpericardiotomy Syndrome | 1 | 2015 | 4 | 0.450 |
Why?
| | Pericardiectomy | 1 | 2015 | 6 | 0.450 |
Why?
| | Autophagy | 2 | 2021 | 199 | 0.450 |
Why?
| | Program Evaluation | 1 | 2016 | 359 | 0.450 |
Why?
| | Colchicine | 1 | 2015 | 25 | 0.450 |
Why?
| | Pericarditis | 1 | 2015 | 20 | 0.440 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2015 | 35 | 0.440 |
Why?
| | Acute Kidney Injury | 5 | 2018 | 399 | 0.440 |
Why?
| | Secondary Prevention | 1 | 2015 | 85 | 0.430 |
Why?
| | Middle Aged | 25 | 2024 | 13419 | 0.430 |
Why?
| | Hypertension | 3 | 2020 | 554 | 0.430 |
Why?
| | Adult | 18 | 2026 | 14534 | 0.420 |
Why?
| | Health Services Needs and Demand | 2 | 2025 | 163 | 0.420 |
Why?
| | Awareness | 1 | 2014 | 26 | 0.420 |
Why?
| | Emigrants and Immigrants | 1 | 2014 | 41 | 0.400 |
Why?
| | Stents | 5 | 2022 | 376 | 0.400 |
Why?
| | Retrospective Studies | 16 | 2026 | 6819 | 0.390 |
Why?
| | United States | 14 | 2025 | 5409 | 0.380 |
Why?
| | Aged | 21 | 2024 | 10429 | 0.370 |
Why?
| | Quality Improvement | 2 | 2024 | 230 | 0.340 |
Why?
| | Hyperglycemia | 2 | 2022 | 90 | 0.340 |
Why?
| | Healthcare Disparities | 3 | 2024 | 312 | 0.340 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 523 | 0.310 |
Why?
| | Prostatic Neoplasms | 2 | 2023 | 401 | 0.310 |
Why?
| | Predictive Value of Tests | 8 | 2022 | 934 | 0.310 |
Why?
| | Risk Factors | 12 | 2023 | 4017 | 0.290 |
Why?
| | Time Factors | 8 | 2020 | 2991 | 0.290 |
Why?
| | Receptors, Glucocorticoid | 2 | 2019 | 34 | 0.290 |
Why?
| | Drug-Eluting Stents | 3 | 2018 | 101 | 0.270 |
Why?
| | Needs Assessment | 2 | 2025 | 145 | 0.270 |
Why?
| | Insulin | 2 | 2021 | 493 | 0.250 |
Why?
| | Algorithms | 3 | 2021 | 667 | 0.250 |
Why?
| | Insulin Infusion Systems | 3 | 2021 | 15 | 0.240 |
Why?
| | Inpatients | 2 | 2025 | 208 | 0.240 |
Why?
| | Length of Stay | 3 | 2026 | 684 | 0.240 |
Why?
| | Angioplasty, Balloon, Coronary | 2 | 2018 | 168 | 0.240 |
Why?
| | Solar Energy | 1 | 2025 | 1 | 0.240 |
Why?
| | Conservation of Natural Resources | 1 | 2025 | 44 | 0.230 |
Why?
| | Child, Hospitalized | 1 | 2025 | 33 | 0.230 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2026 | 158 | 0.230 |
Why?
| | Transcription Factors | 2 | 2019 | 571 | 0.220 |
Why?
| | Hospital Mortality | 5 | 2022 | 457 | 0.220 |
Why?
| | Cooperative Behavior | 1 | 2026 | 233 | 0.210 |
Why?
| | Prospective Studies | 4 | 2024 | 2411 | 0.210 |
Why?
| | Longitudinal Studies | 2 | 2024 | 774 | 0.210 |
Why?
| | Ambulatory Care | 1 | 2025 | 239 | 0.200 |
Why?
| | Receptors, CXCR | 1 | 2023 | 1 | 0.200 |
Why?
| | Prevalence | 2 | 2025 | 1034 | 0.200 |
Why?
| | Odds Ratio | 4 | 2017 | 567 | 0.200 |
Why?
| | Receptors, Androgen | 1 | 2023 | 48 | 0.190 |
Why?
| | Social Environment | 1 | 2023 | 82 | 0.190 |
Why?
| | Endocrinology | 1 | 2022 | 11 | 0.190 |
Why?
| | Child | 6 | 2026 | 7379 | 0.190 |
Why?
| | Insurance | 1 | 2022 | 10 | 0.190 |
Why?
| | Heart Failure | 2 | 2018 | 531 | 0.180 |
Why?
| | Atrophy | 2 | 2019 | 48 | 0.180 |
Why?
| | Hypotension, Controlled | 1 | 2021 | 3 | 0.180 |
Why?
| | Keratinocytes | 2 | 2019 | 91 | 0.170 |
Why?
| | Hypoglycemia | 2 | 2023 | 62 | 0.170 |
Why?
| | R-SNARE Proteins | 1 | 2021 | 7 | 0.170 |
Why?
| | Remote Sensing Technology | 1 | 2021 | 2 | 0.170 |
Why?
| | Multivariate Analysis | 3 | 2017 | 598 | 0.170 |
Why?
| | Minority Groups | 1 | 2022 | 136 | 0.170 |
Why?
| | Phosphorylation | 2 | 2021 | 533 | 0.170 |
Why?
| | Conserved Sequence | 1 | 2021 | 55 | 0.170 |
Why?
| | Patient Readmission | 2 | 2026 | 251 | 0.170 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 487 | 0.170 |
Why?
| | Heart Valve Prosthesis | 1 | 2022 | 89 | 0.170 |
Why?
| | Aortic Valve Stenosis | 1 | 2022 | 79 | 0.170 |
Why?
| | Protein Conformation | 1 | 2021 | 174 | 0.160 |
Why?
| | Aorta | 2 | 2019 | 172 | 0.160 |
Why?
| | Pericardium | 1 | 2020 | 32 | 0.160 |
Why?
| | Reproducibility of Results | 2 | 2021 | 1219 | 0.160 |
Why?
| | Telemedicine | 2 | 2024 | 512 | 0.160 |
Why?
| | Models, Molecular | 1 | 2021 | 352 | 0.160 |
Why?
| | Heart-Assist Devices | 2 | 2018 | 157 | 0.160 |
Why?
| | Enbucrilate | 1 | 2019 | 6 | 0.150 |
Why?
| | Area Under Curve | 2 | 2016 | 185 | 0.150 |
Why?
| | Follow-Up Studies | 4 | 2018 | 2318 | 0.150 |
Why?
| | Tissue Adhesives | 1 | 2019 | 15 | 0.150 |
Why?
| | Arterial Pressure | 1 | 2019 | 44 | 0.150 |
Why?
| | Heart Injuries | 1 | 2019 | 16 | 0.150 |
Why?
| | Prognosis | 4 | 2018 | 2118 | 0.150 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2019 | 7 | 0.150 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 83 | 0.140 |
Why?
| | Critical Illness | 1 | 2021 | 316 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2019 | 171 | 0.140 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2019 | 148 | 0.140 |
Why?
| | Exercise Test | 2 | 2016 | 137 | 0.140 |
Why?
| | Glucagon | 1 | 2017 | 24 | 0.130 |
Why?
| | Sirolimus | 1 | 2018 | 72 | 0.130 |
Why?
| | Hormones | 1 | 2017 | 58 | 0.130 |
Why?
| | Atrial Fibrillation | 2 | 2016 | 197 | 0.130 |
Why?
| | Population Surveillance | 1 | 2018 | 164 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 177 | 0.130 |
Why?
| | Cell Survival | 1 | 2019 | 600 | 0.130 |
Why?
| | Patient Discharge | 2 | 2018 | 325 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.130 |
Why?
| | Hyperemia | 1 | 2016 | 17 | 0.130 |
Why?
| | Lower Extremity | 1 | 2017 | 103 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2017 | 1049 | 0.130 |
Why?
| | Angina, Stable | 1 | 2016 | 7 | 0.130 |
Why?
| | Recurrence | 2 | 2016 | 694 | 0.120 |
Why?
| | Angina, Unstable | 1 | 2016 | 25 | 0.120 |
Why?
| | Incidence | 5 | 2018 | 1085 | 0.120 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 1925 | 0.120 |
Why?
| | Peripheral Arterial Disease | 1 | 2017 | 84 | 0.120 |
Why?
| | Adenosine | 1 | 2016 | 72 | 0.120 |
Why?
| | Vasodilator Agents | 1 | 2016 | 90 | 0.120 |
Why?
| | Transcriptome | 1 | 2019 | 367 | 0.120 |
Why?
| | Chest Pain | 1 | 2016 | 55 | 0.120 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 178 | 0.120 |
Why?
| | New York | 2 | 2025 | 52 | 0.120 |
Why?
| | Vascular Surgical Procedures | 1 | 2017 | 171 | 0.120 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 210 | 0.110 |
Why?
| | Cells, Cultured | 1 | 2019 | 1569 | 0.110 |
Why?
| | Hypoglycemic Agents | 1 | 2017 | 227 | 0.110 |
Why?
| | Constriction, Pathologic | 1 | 2015 | 91 | 0.110 |
Why?
| | Protein Transport | 1 | 2015 | 168 | 0.110 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 252 | 0.110 |
Why?
| | Tubulin Modulators | 1 | 2015 | 28 | 0.110 |
Why?
| | Vascular Patency | 1 | 2015 | 88 | 0.110 |
Why?
| | Acute Coronary Syndrome | 1 | 2016 | 107 | 0.110 |
Why?
| | Endovascular Procedures | 1 | 2017 | 193 | 0.110 |
Why?
| | Serositis | 1 | 2014 | 1 | 0.110 |
Why?
| | Extracellular Matrix Proteins | 1 | 2015 | 69 | 0.110 |
Why?
| | Cerebral Hemorrhage | 1 | 2015 | 102 | 0.110 |
Why?
| | Tissue Engineering | 1 | 2015 | 74 | 0.110 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 135 | 0.110 |
Why?
| | Brain Ischemia | 1 | 2015 | 162 | 0.100 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 164 | 0.100 |
Why?
| | Arkansas | 2 | 2016 | 2068 | 0.100 |
Why?
| | Calcium | 1 | 2015 | 373 | 0.100 |
Why?
| | Lithium | 1 | 2013 | 35 | 0.100 |
Why?
| | Databases, Factual | 4 | 2017 | 742 | 0.100 |
Why?
| | Bradycardia | 1 | 2013 | 38 | 0.100 |
Why?
| | Infant | 3 | 2026 | 3805 | 0.100 |
Why?
| | Echocardiography, Stress | 1 | 2012 | 9 | 0.100 |
Why?
| | Child, Preschool | 3 | 2026 | 4162 | 0.100 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 274 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 392 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 238 | 0.090 |
Why?
| | Clostridium septicum | 1 | 2012 | 2 | 0.090 |
Why?
| | Aortitis | 1 | 2012 | 4 | 0.090 |
Why?
| | Dyspnea | 1 | 2012 | 78 | 0.090 |
Why?
| | Patient Satisfaction | 1 | 2014 | 292 | 0.090 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2016 | 268 | 0.090 |
Why?
| | Plaque, Atherosclerotic | 1 | 2012 | 45 | 0.090 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2016 | 289 | 0.090 |
Why?
| | Stroke Volume | 1 | 2012 | 150 | 0.090 |
Why?
| | Mice | 2 | 2019 | 5982 | 0.090 |
Why?
| | Clostridium Infections | 1 | 2012 | 56 | 0.090 |
Why?
| | New York City | 2 | 2025 | 26 | 0.090 |
Why?
| | HIV Infections | 1 | 2015 | 402 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2018 | 1099 | 0.080 |
Why?
| | Clinical Competence | 1 | 2014 | 406 | 0.080 |
Why?
| | Stroke | 1 | 2015 | 520 | 0.080 |
Why?
| | Logistic Models | 3 | 2017 | 947 | 0.080 |
Why?
| | Hospitals | 2 | 2022 | 181 | 0.080 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 1723 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 1180 | 0.080 |
Why?
| | Cell Proliferation | 2 | 2023 | 1031 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2023 | 1470 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2025 | 2913 | 0.070 |
Why?
| | Registries | 2 | 2021 | 652 | 0.060 |
Why?
| | Animals | 2 | 2019 | 13526 | 0.060 |
Why?
| | Risk Assessment | 2 | 2023 | 1368 | 0.060 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 291 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 1232 | 0.060 |
Why?
| | Social Work | 1 | 2025 | 23 | 0.060 |
Why?
| | Hospitals, Pediatric | 1 | 2025 | 243 | 0.050 |
Why?
| | Comorbidity | 2 | 2016 | 638 | 0.050 |
Why?
| | Acyltransferases | 1 | 2023 | 24 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2025 | 299 | 0.050 |
Why?
| | Sepsis | 2 | 2016 | 240 | 0.050 |
Why?
| | Androgens | 1 | 2023 | 70 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2026 | 530 | 0.050 |
Why?
| | Pilot Projects | 1 | 2024 | 726 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 206 | 0.040 |
Why?
| | Societies, Medical | 1 | 2022 | 207 | 0.040 |
Why?
| | Caregivers | 1 | 2024 | 247 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 21 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2021 | 16 | 0.040 |
Why?
| | Parity | 1 | 2020 | 46 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2024 | 325 | 0.040 |
Why?
| | Evolution, Molecular | 1 | 2021 | 97 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2023 | 317 | 0.040 |
Why?
| | Monitoring, Ambulatory | 1 | 2020 | 9 | 0.040 |
Why?
| | Aortic Valve | 1 | 2022 | 130 | 0.040 |
Why?
| | Ischemia | 1 | 2021 | 158 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2021 | 68 | 0.040 |
Why?
| | Calibration | 1 | 2020 | 58 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 37 | 0.040 |
Why?
| | Cell Membrane | 1 | 2021 | 233 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 93 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 396 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 3494 | 0.040 |
Why?
| | Sex Factors | 1 | 2022 | 747 | 0.040 |
Why?
| | Materials Testing | 1 | 2019 | 55 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 243 | 0.040 |
Why?
| | Protein Binding | 1 | 2021 | 670 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2021 | 315 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2023 | 868 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2021 | 221 | 0.040 |
Why?
| | Attitude of Health Personnel | 1 | 2022 | 371 | 0.040 |
Why?
| | Catheterization | 1 | 2019 | 95 | 0.040 |
Why?
| | Amino Acids | 1 | 2021 | 382 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 411 | 0.030 |
Why?
| | Steroids | 1 | 2018 | 61 | 0.030 |
Why?
| | Limb Salvage | 1 | 2017 | 43 | 0.030 |
Why?
| | Body Weight | 1 | 2020 | 524 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 1557 | 0.030 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2018 | 107 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2020 | 287 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2018 | 266 | 0.030 |
Why?
| | Hospital Costs | 1 | 2017 | 74 | 0.030 |
Why?
| | Population Growth | 1 | 2016 | 2 | 0.030 |
Why?
| | Liver Failure | 1 | 2016 | 21 | 0.030 |
Why?
| | Chronic Disease | 1 | 2019 | 580 | 0.030 |
Why?
| | Phenotype | 1 | 2020 | 803 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 241 | 0.030 |
Why?
| | Signal Transduction | 1 | 2023 | 1748 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2018 | 253 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 170 | 0.030 |
Why?
| | Counseling | 1 | 2016 | 141 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 246 | 0.030 |
Why?
| | Self Care | 1 | 2016 | 136 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 445 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 949 | 0.030 |
Why?
| | Long-Term Care | 1 | 2015 | 50 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 595 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2016 | 119 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2015 | 43 | 0.030 |
Why?
| | Incidental Findings | 1 | 2015 | 43 | 0.030 |
Why?
| | Arthritis, Psoriatic | 1 | 2014 | 8 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2015 | 67 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 179 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2016 | 293 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 245 | 0.030 |
Why?
| | Internal Medicine | 1 | 2014 | 20 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2015 | 547 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 52 | 0.030 |
Why?
| | Survival Analysis | 1 | 2015 | 659 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2015 | 254 | 0.030 |
Why?
| | Pregnancy | 1 | 2020 | 2608 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 1517 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2017 | 445 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 205 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 274 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1112 | 0.020 |
Why?
| | Internship and Residency | 1 | 2014 | 439 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 830 | 0.010 |
Why?
|
|
Agarwal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|